Evidence map›Paper›PMID 34064268›Full record

ArticleGenes2021

What Is Abnormal in Normal Karyotype Acute Myeloid Leukemia in Children? Analysis of the Mutational Landscape and Prognosis of the TARGET-AML Cohort.

Morten Krogh Herlin, Sara A Yones, Eigil Kjeldsen, Linda Holmfeldt, Henrik Hasle

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Morten Krogh HerlinDepartment of Pediatrics and Adolescent Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark.ORCID 0000-0001-7179-4643
Sara A YonesScience for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, 75185 Uppsala, Sweden.
Eigil KjeldsenDepartment of Hematology, Aarhus University Hospital, 8200 Aarhus N, Denmark.
Linda HolmfeldtDepartment of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, 75185 Uppsala, Sweden.ORCID 0000-0003-4140-3423
Henrik HasleDepartment of Pediatrics and Adolescent Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark.
Aarhus University · DKUppsala University · SEAarhus University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Normal karyotype acute myeloid leukemia (NK-AML) constitutes 20-25% of pediatric AML and detailed molecular analysis is essential to unravel the genetic background of this group. Using publicly available sequencing data from the TARGET-AML initiative, we investigated the mutational landscape of NK-AML in comparison with abnormal karyotype AML (AK-AML). In 164 (97.6%) of 168 independent NK-AML samples, at least one somatic protein-coding mutation was identified using whole-genome or targeted capture sequencing. We identified a unique mutational landscape of NK-AML characterized by a higher prevalence of mutated

Indexed as

Abnormal KaryotypeMutation RateAdolescentCCAAT-Enhancer-Binding ProteinsChildChild, PreschoolDioxygenasesDNA-Binding ProteinsFemalefms-Like Tyrosine Kinase 3GATA2 Transcription FactorHumansInfantLeukemia, Myeloid, AcuteMaleNucleophosminCCAAT-Enhancer-Binding ProteinsCEBPA protein, humanDioxygenasesDNA-Binding ProteinsFLT3 protein, humanfms-Like Tyrosine Kinase 3GATA2 protein, humanGATA2 Transcription FactorNPM1 protein, humanNucleophosminProtein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene Proteins p21(ras)PTPN11 protein, humanTET2 protein, humanWT1 protein, humanWT1 Proteinscancer geneticscytogenetically normalcytogeneticsdiagnosismolecular geneticsmutational landscapenormal karyotypepediatric acute myeloid leukemiaprognosissurvival

Identifiers

PMID34064268
PMCPMC8224370
OpenAlexW3163590307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.